

# Disclosure of Relevant Financial or Non-financial/Strategic Business Relationships or Partnerships

## The American Society of Breast Surgeons 24<sup>th</sup> Annual Meeting

### General Session

Thursday, April 27<sup>th</sup> – Sunday, April 30<sup>th</sup>, 2023  
Boston, MA

The Society is charged with ensuring its CME activities are balanced, independent, objective, and scientifically rigorous, through, but not limited to, by identifying and mitigating relevant financial relationships or non-financial/strategic business relationships or partnerships (relationships) between individuals in control of educational content and ineligible companies. By identifying and mitigating relevant relationships, we work together to create a protected space to learn, teach, and engage in scientific discourse free from influence from individuals that may have an incentive to insert commercial bias into a CME activity.

As a CME provider accredited by the [Accreditation Council for Continuing Medical Education \(ACCME\)](#), the ASBrS requires individuals in a position to control the educational content of a CME activity (including but not limited to, course/program chairs, moderators, faculty, authors, content reviewers, editors, planning committees, and ASBrS staff) to disclose all financial and non-financial/strategic business relationships or partnerships (relationships) with ACCME-defined ineligible company, within the 24 months prior to their involvement with the CME activity.

Individuals must review and adhere to the ASBrS CME Activity Policy and Disclosure Process as well as complete the applicable ASBrS Disclosure Form at the time they are invited to participate in a CME activity. Participation is not confirmed without the completion of the disclosure form and will be contingent upon mitigation, if necessary.

Owners or employees of ineligible companies are excluded from controlling content or participating as planners or faculty in a CME activity. The **owners** and **employees** of ineligible companies are considered to have unresolvable financial relationships and must be excluded from participating as planners or faculty and must not be allowed to influence or control any aspect of the planning, delivery, or evaluation of accredited continuing education.

There are three exceptions to this exclusion—employees of ineligible companies can participate as planners or faculty in these specific situations:

- When the content of the activity is not related to the business lines or products of their employer/company.
- When the content of the accredited activity is limited to basic science research, such as pre-clinical research and drug discovery, or the methodologies of research, and they do not make care recommendations.
- When they are participating as technicians to teach the safe and proper use of medical devices, and do not recommend whether or when a device is used.

To assist all CME planners and contributors in identifying relevant relationships, ASBrS staff provides a sample list of typical relevant relationships and possible methods for mitigation—as well as examples of non-compliant actions. However, this list is not an exhaustive list of all scenarios. Participants are required to disclose all possible competing interests, both financial and non-financial, that could interfere with, or could reasonably be perceived as interfering with, their ability to provide objective and valuable contributions to the ASBrS CME activity.

All identified relevant relationships are mitigated prior to the education activity being delivered to learners per ACCME Standards. The inability to mitigate an identified relevant relationship results in the participant's withdrawal from participation in the CME activity.

A list of disclosures from all CME planners and contributors, as well as all potential and actual mitigation methods (including any instances of non-compliance), are documented and maintained by ASBrS staff. This list is made available to all CME activity planners.

The non-compliance process is initiated when an individual's (in a position to control educational content of the CME activity) *undisclosed* relationship(s) with an ineligible company is identified or reported during or after the CME

activity. The Board of Directors, CME Committee, Ethics Committee, and applicable committee chair(s) will discuss the act of noncompliance and agree upon a resolution.

**Oversight**

The CME Committee and Ethics Committees ensure that there is no commercial bias or influence in ASBrS CME activities. They work together to ensure proper conflict management. Members of these committees serve as additional oversight, participating and observing ASBrS CME activities to look for any evidence of bias and ensure compliance with the ASBrS policies.

**Reporting Conflicts**

Participants of any ASBrS CME activity may report any improprieties on the applicable evaluation form and to the CME and Ethics Committee at [cme@breastsurgeons.org](mailto:cme@breastsurgeons.org).

Please note we have advised speakers it is their responsibility to also disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

**The following individuals and groups have been involved in the planning, implementation, approval, and/or evaluation of this activity:**

Course Faculty				
All relevant disclosed relationships have been mitigated by a designated CME Committee Official				
Name	NOTHING TO DISCLOSE	All Relationship(s) with ineligible companies within the past 24 Months	Faculty Relationship(s) Relevant to Participation/Presentation – Yes/No	CME Committee Mitigation for Relevant Relationship(s)
Brigid Killelea, MD		EndoMag; Honorarium, Travel	No	
Nathalie Johnson, MD, FACS		TME; Honorarium; Speaker Panel (Relationship Ended)	No	
Ronda Henry-Tillman, MD, FACS	X			
Constance Lehman, MD		Clairity, Inc.; consultant fees and equity; Co-founder and consultant (Ownership Interest)	Yes	Dr. Lehman's educational content has been peer reviewed; clinical recommendations are free of commercial bias and the content of the presentation does not promote commercial material.
		GE Healthcare; Institutional research funding, honorarium; Researcher, speaker		
Kelly Hunt, MD, FACS		Armada Health; Stipend; Medical Advisory Board	No	
		AstraZeneca; stipend; Medical Advisory Board		

		Cairn Surgical; Funding to institution; Researcher		
		Eli Lilly & Co.; Research funding to institution; Researcher		
		Lumicell; Research funding to institution; Researcher		
Richard Fine, MD, FACS		Hologic; Honorarium; Consultant (Relationship Ended)	<b>No</b>	
		IceCure; Local site PI for the Ice3 Trials		
Walton Taylor, MD, FACS		Impedimed; honoraria; consultant	<b>No</b>	
		TME; honorarium and expenses; Owner, consultant (Owner, Relationship Ended)		
		Aptitude health; honorarium; consultant		
Katharine Yao, MD	X			
Puneet Singh, MD, FACS	X			
Nora Hansen, MD, FACS		Merck; Faculty Forum; honorarium	<b>No</b>	
Jennifer Bellon, MD, FACS		Varian; Honorarium; Educational consultant	<b>No</b>	
		UpToDate; Honorarium/Royalties ; Online medical encyclopedia		
Cory Donovan, MD	X			
Carla Fisher, MD, MBA, FACS		Dilon Technologies; consultant	<b>No</b>	
Terry Sarantou, MD, MS, FACS, FSSO	<b>X</b>			
Rache Simmons, MD, MBA, MS, FACS	<b>X</b>			

Elizabeth Mittendorf, MD, PhD, FACS		BioNTech; Honarium; Scientific Advisory Board (Relationship Ended)	<b>Yes</b>	Dr. Mittendorf's educational content has been peer reviewed; clinical recommendations are free of commercial bias and the content of the presentation does not promote commercial material.
		BMS; Steering committee member		
		Roche/Genentech; Steering Committee member		
		Gilead; Clinical trial support to institution		
Anne Peled, MD		Stryker; Honarium; Consultant/Speaker	<b>No</b>	
		Axogen; Honarium; Consultant/Speaker		
		Mammotome; Honarium; Consultant/Speaker		
		Sientra; Honarium; Consultant/Speaker		
		Allergan; Honarium; Consultant/Speaker		
		Hologic; Honarium; Consultant/Speaker		
Tina Hieken, MD, FACS		Genentech; grant support; Research funding to institution	<b>No</b>	
		SkylineDX BV; grant support; Research funding to institution		
Mediget Teshome, MD, MPH, FACS		Endomagnetics, LTD; Expenses (Relationship Ended)	<b>No</b>	
Katherine Kramme, DO	<b>X</b>			
Clara Farley, MD	<b>X</b>			
Elizabeth Berger, MD, MS	<b>X</b>			
Ton Wang, MD	<b>X</b>			

Barbara Smith, MD		Lumicell, Inc.; Non-financial, NIH-supported research collaboration	<b>Yes</b>	Dr. Smith's educational content has been peer reviewed; clinical recommendations are free of commercial bias and the content of the presentation does not promote commercial material.
Heather McArthur, MD, MPH		Merck; Honorarium, travel accommodations; advisor AstraZeneca; Honorarium; Steering Committee Member Daiichi-Sankyo; honorarium; advisor Crown Bioscience; honorarium; advisor Gilead; honorarium; advisor Puma; honorarium; advisor	<b>No</b>	
Jill Dietz, MD, MHCM, FACS;		Peace Medical Consulting LLC.; Honorarium, Expenses, Consulting fees; Part Owner	<b>No</b>	
Shawna Willey, MD, FACS		Videra Surgical ; Honorarium ; Speaker EndoMagnetics; Honorarium, travel expenses; Speaker Lumicell; Honorarium; Member, DSMB Pacira Pharmaceuticals ; Honorarium, travel expenses; Speaker Medtronic; Honorarium, travel expenses; Speaker Hologic; Honorarium, travel expenses; Speaker TransMed 7; Scientific Adviser (Ownership Interest)	<b>No</b>	

		TME/Aptitude; Honorarium, travel expenses; Consultant		
Alyssa Throckmorton, MD, FACS		TME; honorarium, accomodations, travel; advisor (Relationship Ended)	<b>No</b>	
		Gilead Sciences; stock; stock ownership		
Jo Shapiro, MD, FACS	<b>X</b>			
Leigh Neumayer, MD, FACS	<b>X</b>			
Julie Margenthaler, MD, FACS	<b>X</b>			
Susan Boolbol, MD, FACS		Peace Medical; Honorarium; Executive role (Owner)	<b>No</b>	
Sarah Blair, MD, FACS	<b>X</b>			
Emilia Diego, MD, FACS	<b>X</b>			
Karen Wonders, PhD, FACSM	<b>X</b>			
Kai Huang, MD	<b>X</b>			
Frances Wright, MD, FRCSC	<b>X</b>			
Robert Pride, MD	<b>X</b>			
Abida Sattar, MD	<b>X</b>			
Courtney Vito, MD, FACS		TME; Honorarium, Expenses; Consultant Fee (Relationship Ended)	<b>No</b>	
Stephanie Young, MD, MPH	<b>X</b>			
Kyra Nicholson, MD	<b>X</b>			

Elsa Chahine, MD	X			
Eve Klenotic, DO, FACS	X			
Javier Orozco, MD	X			
J. Michael Dixon, OBE, MD	X			
Michael Alvarado, MD, FACS	X			
Monica Morrow, MD, FACS		Roche; Honorarium; Speaker (Relationship Ended)	No	
		Exact Sciences; Honoraria; Speaker (Relationship Ended)		
Lauren Postlewait, MD, FACS	X			
Miraj Shah-Khan, MD, FACS	X			
Ashley Cairns, MD	X			
Zahraa Al-Hilli, MD	X			
Rita Mukhtar, MD	X			
Max Meneveau, MD	X			
Molly Benolken, MD	X			
Nicole Goldhaber, MD	X			
Neslihan Cabioglu, MD, PhD	X			
Anna Beck, MD	X			

Kathie-Ann Joseph, MD, MPH, FACS	X			
Lisa Newman, MD, MPH, FACS, FASCO	X			
Sharon Lum, MD, MBA, FACS	X			
Jane Mendez, MD, FACS	X			
Jo Buyske, MD, FACS	X			
Helen Pass, MD, FACS		Exact Sciences; Honorarium; speaker	No	
		Endomag; Honorarium; speaker		
Jay Harness, MD, FACS		Medtronic Enabling Technology; Honorarium; Speaker	No	
		Lumicell; Honorarium; Chair- Data Safety Monitoring Board		
Sarah McLaughlin, MD, FACS	X			
Kathryn Schmitz, PhD, MPH	X			
Liz O'Riordan, MD, PhD	X			
Ashley Crowell, MS, PA-C	X			
Kari Rosenkranz, MD, FACS	X			
Betty Fan, DO, FACOS	X			
Anna Weiss, MD, FACS	X			
Jennifer Gass, MD, FACS	X			



Judy Boughey, MD, FACS		Eli Lilly; research funding (institute); Researcher	No	
		SymBioSis; Research funding; Consultant		
		CairnsSurgical; expenses; DSMB		
		UptoDate; royalties		
		PER and PeerView; honorarium; speaker (Relationship Ended)		
		EndoMag; Travel, accomodation, honorarium; speaker (Relationship Ended)		
Ted James, MD, MHCM, FACS		Perimeter; Honorarium/Options; Advisory Board	No	
E. Shelley Hwang, MD, MPH, FACS		Merck; Speakers' Bureau	No	
		Astra Zeneca; Consultant		
		Higgs Bonson; Honorarium; steering committee		
		Clinetic; Honorarium; steering committee		
		Immunis; consultant		
Jennifer Garreau, MD	X			
Laura Esserman, MD, FACS		Merck; Research funding to Institute; Investigator initiated trial of DCIS	No	
Hiram Cody, MD, FACS	X			
Melissa Pilewskie, MD, FACS	X			
Tari King, MD, FACS, FSSO		Exact Sciences; Honorarium; Advisory board member,	No	

		speaker (Relationship Ended)		
Steve Cai, MD, FACS		Ambry Genetics; Honorarium; Speaker	<b>No</b>	
		Hologic; Honorarium; Consultant, speaker		
Christine Klassen, MD	<b>X</b>			
Jennifer Plichta, MD, MS, FACS	<b>X</b>			
Andrea Barrio, MD, FACS	<b>X</b>			
Sheldon Feldman, MD, FACS	<b>X</b>			
V. Suzanne Klimberg, MD, PhD, MSHCT, FACS	<b>X</b>			
Michael Cassidy, MD, FACS	<b>X</b>			
Katrina Mitchell, MD, FACS	<b>X</b>			
Sylvia Reyes, MD, MBS, FACS	<b>X</b>			
Jennifer Tseng, MD, FACS		Stryker; Travel Expenses; Training Course (Relationship Ended)	<b>No</b>	
		Envisio; Travel Expenses; Training Course (Relationship Ended)		

Board of Directors	NOTHING TO DISCLOSE	DISCLOSURE (All relationships with ineligible companies within the past 24 months)		
NAME		All board members recused themselves from discussions and decisions where a conflict of interest could occur.		
		Company	Received	Role
Michael Berry, MD		TransMed7 (2019-present)	Stock	
		TME (2021, 2022)	Honorarium	
Susan Boolbol, MD		Peace Medical Consultants, LLC		Executive role

Jill Dietz, MD		Peace Medical Consultants, LLC	Honorarium and expenses and consulting fees	Part Owner
Ronda Henry-Tillman, MD	X			
Kevin Hughes, MD		Volpara (January 2021)	Honorarium	Speaker
		Hologic (Surgical implant for radiation planning with breast conservation and wire free breast biopsy)	Honoraria/consulting fees	Speaker/consultant
		TME (Targeted Medical Education, genetics education and consulting)	Honoraria/consulting fees	Speaker/consultant
		Invitae (Genetics company)	Honoraria/consulting fees	Speaker/consultant
		23&Me(Genetics company)	Honoraria/consulting fees	Speaker/consultant
		Ambry(Genetics company)	Honoraria/consulting fees	Speaker/consultant
		CRA Health (Formerly Hughes RiskApps)		Founder
Nathalie Johnson, MD		TME (2021)	Honorarium	Speaker Panel
Eric Manahan, MD		Astrazeneca (2021)		
		TME (2022)		
		Myriad Genetics (2021)		
Julie Margenthaler, MD	X			
Jane Mendez, MD	X			
Toan Nguyen, MD		TME (2021, 2022)	Honorarium	

Annual Meeting Committee		
Name	NOTHING TO DISCLOSE	All relationships with ineligible companies within the past 24 months). All committee members recused themselves from discussions and decisions where a conflict of interest could occur.
Brigid Killelea, MD (2023 Program Chair)	X	
Sarah Blair, MD (Publications Committee Co-Chair)	X	
Susan K. Boolbol, MD (President-Elect)		Peace Medical; Honorarium; Executive role
Jill Dietz, MD (Chairman of the Board)		Peace Medical Consulting LLC.; Honorarium and expenses and consulting fees; Part Owner
Carla Fisher, MD (2022 Program Chair)		Dilon Technologies; consultant
Jennifer Gass, MD (2024 Program Chair)	X	
Nathalie Johnson, MD (President)		TME; Honorarium; Speaker Panel (Relationship Ended)

Eric Manahan, MD (Secretary/Treasurer)		Astrazeneca; Speaker; Honoraria TME ; Consultant/Speaker (Relationship Ended) Myriad Genetics; (Relationship Ended)
Julie Margenthaler, MD (Immediate Past President)	X	
Mediget Teshome, MD (Publications Committee Co-Chair)		Endomagnetics, LTD; Expenses (Relationship Ended)
Shawna Willey, MD (Interim Corporate Relations Chair)		Videra Surgical ; Honorarium ; Speaker EndoMagnetics; Honorarium, travel expenses; Speaker Lumicell; Honorarium; Member, DSMB Pacira Pharmaceuticals ; Honorarium, travel expenses; Speaker Medtronic; Honorarium, travel expenses; Speaker Hologic; Honorarium, travel expenses; Speaker TransMed 7 ; Nothing; Scientific Adviser (Ownership Interest) TME/Aptitude; Honorarium, travel expenses; Consultant

<b>CME Committee</b>				
<b>NAME</b>	<b>NOTHING TO DISCLOSE</b>	<b>DISCLOSURE (All relationships with ineligible companies within the past 24 months)</b>		
		<b>Company</b>	<b>Received</b>	<b>Role</b>
Joseph Contino, MD	X			
Lynn Dengel, MD	X			
Jillian Lloyd, MD	X			
Sarah McLaughlin, MD (Chair)	X			

<b>Ethics Committee (Oversight)</b>				
<b>NAME</b>	<b>NOTHING TO DISCLOSE</b>	<b>DISCLOSURE (All relationships with ineligible companies within the past 24 months) All committee members recused themselves from discussions and decisions where a conflict of interest could occur.</b>		
		<b>Company</b>	<b>Received</b>	<b>Role</b>
Lisa Allen, MD	X			
Emily Bellavance, MD	X			
Katherina Zabicki-Calvillo, MD	X			
Tina Hieken, MD		Genentech	Research Funding to Institution	Co-PI, Clinical Lead
		SkylineDx	Research Funding to Institution	Co-PI
David Kaufman, MD	X			

Cindy Matsen, MD	X			
Toan Nguyen, MD (Chair)		Targeted Medical Education (TME)	Honorarium	Consultant
	X			
Puneet Singh, MD	X			
Paige Teller, MD	X			
Sarah Tevis, MD	X			
Jennifer Tseng, MD	X			

<b>ASBrS Staff</b>				
<b>NAME</b>	<b>NOTHING TO DISCLOSE</b>	<b>DISCLOSURE (All relationships with ineligible companies within the past 24 months)</b>		
		<b>Company</b>	<b>Received</b>	<b>Role</b>
Marta Boyer, Director, Strategic Partnerships	X			
Erica J. Holland, Executive Director	X			
Christina Lucara, Meetings and Education Manager	X			
Patricia Lovell, CME Assistant	X			
Tekoah White, CME Manager	X			